Microbiome, trimethylamine N-oxide, and cardiometabolic disease

Translational Research

Volumn 179, Issue , 2017, Pages 108-115

  Tang, W H Wilson ^a   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIMETHYLAMINE OXIDE; METHYLAMINE; TRIMETHYLOXAMINE;

BACTERIAL METABOLISM; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; FOOD INTAKE; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTESTINE FLORA; METABOLIC DISORDER; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; ANIMAL; CARDIOVASCULAR DISEASES; METABOLIC DISEASES; METABOLISM; MICROBIOLOGY; MICROFLORA;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; METHYLAMINES; MICROBIOTA;

EID: 84981734356     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.07.007     Document Type: Review

References (57)

1. 1 Aron-Wisnewsky, J., Clement, K., The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat Rev Nephrol 12 (2016), 169–181.
2. 2 Brown, J.M., Hazen, S.L., The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med 66 (2015), 343–359.
3. 3 Tang, W.H., Hazen, S.L., The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 124 (2014), 4204–4211.
4. 4 Tang, W.H., Wang, Z., Levison, B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368 (2013), 1575–1584.
5. 5 Wang, Z., Klipfell, E., Bennett, B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
6. 6 Koeth, R.A., Wang, Z., Levison, B.S., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19 (2013), 576–585.
7. 7 Koeth, R.A., Levison, B.S., Culley, M.K., et al. Gamma-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of l-carnitine to TMAO. Cell Metab 20 (2014), 799–812.
8. 8 Wang, Z., Tang, W.H., Buffa, J.A., et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-n-oxide. Eur Heart J 35 (2014), 904–910.
9. 9 Hartiala, J., Bennett, B.J., Tang, W.H., et al. Comparative genome-wide association studies in mice and humans for trimethylamine n-oxide, a proatherogenic metabolite of choline and l-carnitine. Arterioscler Thromb Vasc Biol 34 (2014), 1307–1313.
10. 10 Gregory, J.C., Buffa, J.A., Org, E., et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 290 (2015), 5647–5660.
11. 11 Zhu, W., Gregory, J.C., Org, E., et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165 (2016), 111–124.
12. 12 Li, D., Kirsop, J., Tang, W.H., Listening to our gut: contribution of gut microbiota and cardiovascular risk in diabetes pathogenesis. Curr Diab Rep, 15, 2015, 63.
13. 13 Backhed, F., Ding, H., Wang, T., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101 (2004), 15718–15723.
14. 14 Backhed, F., Manchester, J.K., Semenkovich, C.F., Gordon, J.I., Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 104 (2007), 979–984.
15. 15 Turnbaugh, P.J., Hamady, M., Yatsunenko, T., et al. A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
16. 16 Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
17. 17 Tang, W.H., Wang, Z., Fan, Y., et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-n-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 64 (2014), 1908–1914.
18. 18 Lever, M., George, P.M., Slow, S., et al. Betaine and trimethylamine-n-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study. PLoS One, 9, 2014, e114969.
19. 19 Dambrova, M., Latkovskis, G., Kuka, J., et al. Diabetes is associated with higher trimethylamine n-oxide plasma levels. Exp Clin Endocrinol Diabetes 124 (2016), 251–256.
20. 20 Miao, J., Ling, A.V., Manthena, P.V., et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun, 6, 2015, 6498.
21. 21 Gao, X., Liu, X., Xu, J., Xue, C., Xue, Y., Wang, Y., Dietary trimethylamine n-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng 118 (2014), 476–481.
22. 22 Gao, X., Xu, J., Jiang, C., et al. Fish oil ameliorates trimethylamine n-oxide-exacerbated glucose intolerance in high-fat diet-fed mice. Food Funct 6 (2015), 1117–1125.
23. 23 Warrier, M., Shih, D.M., Burrows, A.C., et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep, 2016, 326–338 http://dx.doi.org/10.1016/j.celrep.2014.12.036.
24. 24 Bennett, B.J., de Aguiar Vallim, T.Q., Wang, Z., et al. Trimethylamine-n-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17 (2013), 49–60.
25. 25 Verbrugge, F.H., Dupont, M., Steels, P., et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 62 (2013), 485–495.
26. 26 Nagatomo, Y., Tang, W.H., Intersections between microbiome and heart failure: revisiting the gut hypothesis. J Card Fail 21 (2015), 973–980.
27. 27 Tang, W.H., Wang, Z., Shrestha, K., et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail 21 (2015), 91–96.
28. 28 Troseid, M., Ueland, T., Hov, J.R., et al. Microbiota-dependent metabolite trimethylamine-n-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med 277 (2015), 717–726.
29. 29 Tang, W.H., Wang, Z., Kennedy, D.J., et al. Gut microbiota-dependent trimethylamine n-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116 (2015), 448–455.
30. 30 Suzuki, T., Heaney, L.M., Bhandari, S.S., Jones, D.J., Ng, L.L., Trimethylamine n-oxide and prognosis in acute heart failure. Heart 102 (2016), 841–848.
31. 31 Organ, C.L., Otsuka, H., Bhushan, S., et al. Choline diet and its gut microbe-derived metabolite, trimethylamine n-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail, 9, 2016, e002314.
32. 32 Pluznick, J., A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 5 (2014), 202–207.
33. 33 Ufnal, M., Jazwiec, R., Dadlez, M., Drapala, A., Sikora, M., Skrzypecki, J., Trimethylamine-n-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin ii in rats. Can J Cardiol 30 (2014), 1700–1705.
34. 34 Yatsunenko, T., Rey, F.E., Manary, M.J., et al. Human gut microbiome viewed across age and geography. Nature 486 (2012), 222–227.
35. 35 Acara, M., Camiolo, S., Rennick, B., Renal n-oxidation of trimethylamine in the chicken during tubular excretion. Drug Metab Dispos 5 (1977), 82–90.
36. 36 Foxall, P.J., Mellotte, G.J., Bending, M.R., Lindon, J.C., Nicholson, J.K., NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Int 43 (1993), 234–245.
37. 37 Le Moyec, L., Pruna, A., Eugene, M., et al. Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation follow-up. Nephron 65 (1993), 433–439.
38. 38 Hai, X., Landeras, V., Dobre, M.A., DeOreo, P., Meyer, T.W., Hostetter, T.H., Mechanism of prominent trimethylamine oxide (TMAO) accumulation in hemodialysis patients. PLoS One, 10, 2015, e0143731.
39. 39 Kaysen, G.A., Johansen, K.L., Chertow, G.M., et al. Associations of trimethylamine n-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis. J Ren Nutr 25 (2015), 351–356.
40. 40 Missailidis, C., Hallqvist, J., Qureshi, A.R., et al. Serum trimethylamine-n-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS One, 11, 2016, e0141738.
41. 41 Stubbs, J.R., House, J.A., Ocque, A.J., et al. Serum trimethylamine-n-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 27 (2016), 305–313.
42. 42 Bell, J.D., Lee, J.A., Lee, H.A., Sadler, P.J., Wilkie, D.R., Woodham, R.H., Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-n-oxide. Biochim Biophys Acta 1096 (1991), 101–107.
43. 43 Bain, M.A., Faull, R., Fornasini, G., Milne, R.W., Evans, A.M., Accumulation of trimethylamine and trimethylamine-n-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 21 (2006), 1300–1304.
44. 44 Lekawanvijit, S., Kompa, A.R., Wang, B.H., Kelly, D.J., Krum, H., Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res 111 (2012), 1470–1483.
45. 45 Rhee, E.P., Clish, C.B., Ghorbani, A., et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 24 (2013), 1330–1338.
46. 46 Shih, D.M., Wang, Z., Lee, R., et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56 (2015), 22–37.
47. 47 Seldin, M.M., Meng, Y., Qi, H., et al. Trimethylamine n-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κb. J Am Heart Assoc, 5, 2016.
48. 48 McEntyre, C.J., Lever, M., Chambers, S.T., et al. Variation of betaine, n,n-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period. Ann Clin Biochem 52 (2015), 352–360.
49. 49 Mi Park, E., Lee, E., Jin Joo, H., Oh, E., Lee, J., Lee, J.S., Inter- and intra-individual variations of urinary endogenous metabolites in healthy male college students using (1)h NMR spectroscopy. Clin Chem Lab Med 47 (2009), 188–194.
50. 50 Albenberg, L.G., Wu, G.D., Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology 146 (2014), 1564–1572.
51. 51 Bain, M.A., Faull, R., Milne, R.W., Evans, A.M., Oral l-carnitine: metabolite formation and hemodialysis. Curr Drug Metab 7 (2006), 811–816.
52. 52 Miller, M.J., Bostwick, B.L., Kennedy, A.D., et al. Chronic oral l-carnitine supplementation drives marked plasma TMAO elevations in patients with organic acidemias despite dietary meat restrictions. JIMD Rep, 2016 http://dx.doi.org/10.1007/8904_2016_539 [Epub ahead of print].
53. 53 Craciun, S., Balskus, E.P., Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A 109 (2012), 21307–21312.
54. 54 Craciun, S., Marks, J.A., Balskus, E.P., Characterization of choline trimethylamine-lyase expands the chemistry of glycyl radical enzymes. ACS Chem Biol 9 (2014), 1408–1413.
55. 55 Zhu, Y., Jameson, E., Crosatti, M., et al. Carnitine metabolism to trimethylamine by an unusual rieske-type oxygenase from human microbiota. Proc Natl Acad Sci U S A 111 (2014), 4268–4273.
56. 56 Romano, K.A., Vivas, E.I., Amador-Noguez, D., Rey, F.E., Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-n-oxide. MBio, 6, 2015, e02481.
57. 57 Wang, Z., Roberts, A.B., Buffa, J.A., et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163 (2015), 1585–1595.